Bio-Rad and 10X Genomics end patent fight with new licensing deal

Bio-Rad Laboratories has settled its long-running dispute with 10X Genomics over patents covering genetic analysis tech and both companies have negotiated an agreement to cross-license their products.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotech

Europe’s missing biotech bridge: Why IP ownership matters more than capital access

17 August 2026 Europe’s biotechnology challenge is not only whether it can fund innovation. It is whether it can continue to originate and control the foundational IP positions from which future biotech value is created. Paul Calvo of Sterne Kessler explains.

Biotech

Masimo keeps $634m smartwatch award and moves to appeal

21 July 2026 Now a Danaher subsidiary, the company is contesting a number of orders after a California court finalised several aspects of the high-profile dispute.

Biotech

Arbutus takes Comirnaty LNP patent fight to Canada and UPC

20 July 2026 The biotech company has launched a trio of lawsuits against two vaccine makers, while announcing receipt of a $178 million sum from Moderna under a previous deal.

More features

Vanda revives challenge over braille-free label on generic sleep disorder drug

Abbott fends off Chinese rival’s patent challenge at UPC

Former head of litigation at Nokia returns to Bird & Bird

Former USPTO acting director takes the helm at C4IP

Europe’s missing biotech bridge: Why IP ownership matters more than capital access

Novartis scores UK win in high-stakes Entresto fight

Invisalign maker secures first China win against clear aligner rival

Holland & Hart adds high-stakes patent litigation team from Ashurst Perkins Coie

Bio-Rad and 10X Genomics end patent fight with new licensing deal

More on this story

Editor's picks

Editor's picks

More features